Ista Pharmaceuticals LLC  

(Public, NASDAQ:ISTA)   Watch this stock  
Find more results for ISTA
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.21
Shares 41.91M
Beta     -
Inst. own 84%

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin -52.35% -35.31%
Operating margin -4.74% 0.01%
EBITD margin - 1.45%
Return on average assets -51.41% -39.40%
Return on average equity - -
Employees 330 -
CDP Score - -

Address

50 Technology Drive
IRVINE, CA 92618
United States - Map
+1-949-7886000 (Phone)
+1-949-7886010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ISTA Pharmaceuticals, Inc. (ISTA) is a commercial-stage, multi-specialty pharmaceutical company. The Company is engaged in developing, marketing and selling its own products in the United States and Puerto Rico. ISTA is a prescription eye care business in the United States and has an allergy drug franchise. ISTA manufactures its finished good products through third-party contracts. ISTA in-licenses or acquires new products and technologies to add to its internal development. Its products and product candidates seek to treat allergy and diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye and ocular and nasal allergies. It has four products available for sale in the United States and Puerto Rico: BROMDAY (bromfenac ophthalmic solution) 0.09%, BEPREVE (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL (timolol maleate ophthalmic solution) 0.5% and VITRASE (hyaluronidase injection).